This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AVEO AVEO Pharmaceuticals (AVEO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About AVEO Pharmaceuticals Stock (NASDAQ:AVEO) 30 days 90 days 365 days Advanced Chart Remove Ads Get AVEO Pharmaceuticals alerts:Sign Up Key Stats Today's Range$14.99▼$15.0050-Day Range$14.90▼$15.0052-Week Range$3.06▼$15.00Volume247,800 shsAverage Volume601,442 shsMarket Capitalization$521.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.Read More… Remove Ads Receive AVEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AVEO Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AVEO Stock News HeadlinesBAFO alert: One more round for Scape, GIC in $3b Aveo saleApril 3 at 3:48 AM | afr.comBig Pharma faces heat as India records 307 drug pricing violationsMarch 25, 2025 | msn.comTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.April 4, 2025 | Porter & Company (Ad)CDSCO eases rules, pharma firms can now get 1-year NoC online via Sugam portalMarch 9, 2025 | msn.comThe Indian company filling West Africa with fake drugsMarch 5, 2025 | msn.comNAFDAC blacklists Indian firm for importing hard drugsMarch 1, 2025 | msn.comNAFDAC blacklists Indian firm for importing hard drugsMarch 1, 2025 | msn.comNAFDAC blacklists Indian pharmaceutical company over production of addictive pillsMarch 1, 2025 | msn.comSee More Headlines AVEO Stock Analysis - Frequently Asked Questions How were AVEO Pharmaceuticals' earnings last quarter? AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) released its earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.36) by $0.06. The biopharmaceutical company had revenue of $15.17 million for the quarter, compared to the consensus estimate of $14.29 million. AVEO Pharmaceuticals had a negative net margin of 30.79% and a negative trailing twelve-month return on equity of 81.66%. When did AVEO Pharmaceuticals' stock split? Shares of AVEO Pharmaceuticals reverse split on Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 19th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of AVEO Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that AVEO Pharmaceuticals investors own include Advanced Micro Devices (AMD), Micron Technology (MU), OPKO Health (OPK), Alibaba Group (BABA), Meta Platforms (META), Exelixis (EXEL) and NVIDIA (NVDA). Company Calendar Last Earnings11/08/2021Today4/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:AVEO CIK1325879 Webwww.aveooncology.com Phone(617) 400-0101Fax617-995-4995Employees114Year Founded2001Profitability EPS (Most Recent Fiscal Year)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-53,340,000.00 Net Margins-30.79% Pretax Margin-30.79% Return on Equity-81.66% Return on Assets-28.83% Debt Debt-to-Equity Ratio0.94 Current Ratio2.37 Quick Ratio2.35 Sales & Book Value Annual Sales$42.29 million Price / Sales12.33 Cash FlowN/A Price / Cash FlowN/A Book Value$1.33 per share Price / Book11.28Miscellaneous Outstanding Shares34,763,000Free Float33,619,000Market Cap$521.45 million OptionableOptionable Beta1.00 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:AVEO) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AVEO Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AVEO Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.